2021 annual financial data
TScan Therapeutics 2021 Operating cash flow margin
Direct answer
Operating cash flow margin was -480%.
Operating income was -48,641,000 USD and net income was -48,625,000 USD.
Operating cash flow was -48,677,000 USD.
Get free TScan Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 10,141,000 USD
- Operating income
- -48,641,000 USD
- Net income
- -48,625,000 USD
- Operating cash flow
- -48,677,000 USD